UNSPSC 51263405: Bretylium tosilate

This classification denotes an antiarrhythmic agent with the molecular formula C11H17BrN.C7H7O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78ZP3YR353, chemically known as 2-bromo-n-ethyl-n,n-dimethylbenzenemethanaminium 4-methylbenzenesulfonate but more generally known as bretylium tosilate, which bears US NIH Compound Identifier 6100. European Medicines Agency schedules Bretylium tosilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05887MIG.

UNSPSC 51263405 Bretylium tosilate is a Commodity code representing a specific pharmaceutical active ingredient, but the recent state and local opportunities posted under this code show minimal direct alignment with bretylium procurement itself. The two identified solicitations — Seminole County's IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs — address broader pharmaceutical and pharmacy benefit management initiatives rather than bretylium-specific acquisition. State and local governments soliciting under this code appear to be county health departments and state health agencies pursuing pharmaceutical goods and services to support community health, opioid response, and prescription benefit management programs. Issuing bodies include county-level health procurement (Seminole County, Florida) and state health agencies (Texas HHS Commission), though the frequency of bretylium-specific solicitations remains unclear from available recent activity.

Geographic activity is limited to Florida and Texas based on recent postings. Seminole County's IFB for naloxone and drug deactivation systems (solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, and included a two-year initial term with one-year renewal option and FEMA funding potential. The Texas Health and Human Services Commission's RFI (HHS0017013, posted April 3, 2026) represented preliminary market intelligence gathering on direct-to-manufacturer prescription fulfillment rather than a formal procurement, designed to inform future RFP development. The code shows sparse recent state and local contract activity explicitly tied to bretylium tosilate procurement; opportunities posted under the code address adjacent pharmaceutical categories and pharmacy program management rather than this specific pharmaceutical ingredient.